Recent studies have found that ITPRIPL1 is commonly observed in tumors with low expression of PD-L1 and the expression of this gene can inhibit T cells in the tumor microenvironment (TME), while antibodies targeting this gene can suppress tumor growth and promote T cell infiltration (Deng et al., 2023; Deng et al., 2024). This evidence concerns the gene ITPRIPL1 and neoplasm.